158 related articles for article (PubMed ID: 29536773)
1. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders.
Benek O; Hroch L; Aitken L; Gunn-Moore F; Vinklarova L; Kuca K; Perez DI; Perez C; Martinez A; Fisar Z; Musilek K
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):665-670. PubMed ID: 29536773
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.
Hroch L; Guest P; Benek O; Soukup O; Janockova J; Dolezal R; Kuca K; Aitken L; Smith TK; Gunn-Moore F; Zala D; Ramsay RR; Musilek K
Bioorg Med Chem; 2017 Feb; 25(3):1143-1152. PubMed ID: 28082069
[TBL] [Abstract][Full Text] [Related]
3. Identification of small-molecule inhibitors of the Abeta-ABAD interaction.
Xie Y; Deng S; Chen Z; Yan S; Landry DW
Bioorg Med Chem Lett; 2006 Sep; 16(17):4657-60. PubMed ID: 16781151
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Hroch L; Benek O; Guest P; Aitken L; Soukup O; Janockova J; Musil K; Dohnal V; Dolezal R; Kuca K; Smith TK; Gunn-Moore F; Musilek K
Bioorg Med Chem Lett; 2016 Aug; 26(15):3675-8. PubMed ID: 27287370
[TBL] [Abstract][Full Text] [Related]
5. Achieving effective and selective CK1 inhibitors through structure modification.
Du C; Yang H; Feng F; Liu W; Chen Y; Sun H
Future Med Chem; 2021 Mar; 13(5):505-528. PubMed ID: 33438471
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol.
Lim YA; Grimm A; Giese M; Mensah-Nyagan AG; Villafranca JE; Ittner LM; Eckert A; Götz J
PLoS One; 2011; 6(12):e28887. PubMed ID: 22174920
[TBL] [Abstract][Full Text] [Related]
7. Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.
Valaasani KR; Sun Q; Hu G; Li J; Du F; Guo Y; Carlson EA; Gan X; Yan SS
Curr Alzheimer Res; 2014 Feb; 11(2):128-36. PubMed ID: 24479630
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.
Morsy A; Trippier PC
J Med Chem; 2019 May; 62(9):4252-4264. PubMed ID: 30444369
[TBL] [Abstract][Full Text] [Related]
9. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases.
Perez DI; Gil C; Martinez A
Med Res Rev; 2011 Nov; 31(6):924-54. PubMed ID: 20577972
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I.
Flajolet M; He G; Heiman M; Lin A; Nairn AC; Greengard P
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4159-64. PubMed ID: 17360493
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Development of Casein Kinase 1 Inhibitors.
Li SS; Dong YH; Liu ZP
Curr Med Chem; 2021; 28(8):1585-1604. PubMed ID: 32660395
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of carbon-11-labeled CK1 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease.
Gao M; Wang M; Zheng QH
Bioorg Med Chem Lett; 2018 Jul; 28(13):2234-2238. PubMed ID: 29859907
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of gamma-secretase by the CK1 inhibitor IC261 does not depend on CK1delta.
Höttecke N; Liebeck M; Baumann K; Schubenel R; Winkler E; Steiner H; Schmidt B
Bioorg Med Chem Lett; 2010 May; 20(9):2958-63. PubMed ID: 20350806
[TBL] [Abstract][Full Text] [Related]
14. Casein kinases as potential therapeutic targets.
Cozza G; Pinna LA
Expert Opin Ther Targets; 2016; 20(3):319-40. PubMed ID: 26565594
[TBL] [Abstract][Full Text] [Related]
15. Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer's Disease Treatment.
Schmidt M; Benek O; Vinklarova L; Hrabinova M; Zemanova L; Chribek M; Kralova V; Hroch L; Dolezal R; Lycka A; Prchal L; Jun D; Aitken L; Gunn-Moore F; Kuca K; Musilek K
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192199
[TBL] [Abstract][Full Text] [Related]
16. ABAD: a potential therapeutic target for Abeta-induced mitochondrial dysfunction in Alzheimer's disease.
Marques AT; Fernandes PA; Ramos MJ
Mini Rev Med Chem; 2009 Jul; 9(8):1002-8. PubMed ID: 19601895
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.
Kissinger CR; Rejto PA; Pelletier LA; Thomson JA; Showalter RE; Abreo MA; Agree CS; Margosiak S; Meng JJ; Aust RM; Vanderpool D; Li B; Tempczyk-Russell A; Villafranca JE
J Mol Biol; 2004 Sep; 342(3):943-52. PubMed ID: 15342248
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Assay Development and HTS of Small-Molecule Human ABAD/17β-HSD10 Inhibitors as Therapeutics in Alzheimer's Disease.
Aitken L; Baillie G; Pannifer A; Morrison A; Jones PS; Smith TK; McElroy SP; Gunn-Moore FJ
SLAS Discov; 2017 Jul; 22(6):676-685. PubMed ID: 28314118
[TBL] [Abstract][Full Text] [Related]
19. Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders.
Catarzi D; Varano F; Vigiani E; Lambertucci C; Spinaci A; Volpini R; Colotta V
Curr Med Chem; 2022; 29(27):4698-4737. PubMed ID: 35232339
[TBL] [Abstract][Full Text] [Related]
20. 3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study.
He XY; Dobkin C; Brown WT; Yang SY
J Alzheimers Dis; 2022; 88(4):1487-1497. PubMed ID: 35786658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
